转移性前列腺癌治疗前景的变化

IF 0.7 1区历史学 Q1 HISTORY

Oral History Review Pub Date : 2017-01-01 DOI:10.17925/OHR.2017.13.02.112

A. Koletsky

{"title":"转移性前列腺癌治疗前景的变化","authors":"A. Koletsky","doi":"10.17925/OHR.2017.13.02.112","DOIUrl":null,"url":null,"abstract":"O ver the past several years a number of novel and diverse agents have provided a significant clinical benefit for patients with metastatic castration-resistant prostate cancer including abiraterone, enzalutamide, sipuleucel-T, cabazitaxel, and radium-223. The early use of docetaxel or abiraterone at initiation of standard androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer has also led to substantial improvements in overall survival. The identification of a truncating mutation in the androgen receptor (ARV7), a biomarker of resistance, may help clarify a more optimal sequencing of hormonal and chemotherapy-based therapies for patients with metastatic disease. The genomic landscape of both primary and metastatic prostate cancer has been an important focal point of translational research. The most widely studied pathways that affect tumorigenesis are the phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homolog (PTEN)/protein kinase B (AKT) and poly ADP ribose polymerase (PARP) and DNA repair pathways. This review will highlight recent clinical trials which have had a major impact on the management of patients with metastatic disease with an emphasis on treatments driven by common genomic aberrations present in advanced prostate cancer.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"13 1","pages":"112"},"PeriodicalIF":0.7000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Changing Therapeutic Landscape in Metastatic Prostate Cancer\",\"authors\":\"A. Koletsky\",\"doi\":\"10.17925/OHR.2017.13.02.112\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"O ver the past several years a number of novel and diverse agents have provided a significant clinical benefit for patients with metastatic castration-resistant prostate cancer including abiraterone, enzalutamide, sipuleucel-T, cabazitaxel, and radium-223. The early use of docetaxel or abiraterone at initiation of standard androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer has also led to substantial improvements in overall survival. The identification of a truncating mutation in the androgen receptor (ARV7), a biomarker of resistance, may help clarify a more optimal sequencing of hormonal and chemotherapy-based therapies for patients with metastatic disease. The genomic landscape of both primary and metastatic prostate cancer has been an important focal point of translational research. The most widely studied pathways that affect tumorigenesis are the phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homolog (PTEN)/protein kinase B (AKT) and poly ADP ribose polymerase (PARP) and DNA repair pathways. This review will highlight recent clinical trials which have had a major impact on the management of patients with metastatic disease with an emphasis on treatments driven by common genomic aberrations present in advanced prostate cancer.\",\"PeriodicalId\":44122,\"journal\":{\"name\":\"Oral History Review\",\"volume\":\"13 1\",\"pages\":\"112\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral History Review\",\"FirstCategoryId\":\"98\",\"ListUrlMain\":\"https://doi.org/10.17925/OHR.2017.13.02.112\",\"RegionNum\":1,\"RegionCategory\":\"历史学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HISTORY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral History Review","FirstCategoryId":"98","ListUrlMain":"https://doi.org/10.17925/OHR.2017.13.02.112","RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HISTORY","Score":null,"Total":0}

引用次数: 0

摘要

在过去的几年中，许多新颖多样的药物为转移性去势抵抗性前列腺癌患者提供了显著的临床益处，包括阿比特龙、恩杂鲁胺、sipuleucel-T、卡巴他赛和镭-223。转移性激素敏感前列腺癌患者在标准雄激素剥夺治疗开始时早期使用多西他赛或阿比特龙也显著提高了总生存率。雄激素受体(ARV7)(一种耐药的生物标志物)的截断突变的鉴定，可能有助于阐明针对转移性疾病患者的激素和化疗为基础的治疗的更优测序。原发性和转移性前列腺癌的基因组景观一直是转化研究的重要焦点。影响肿瘤发生的最广泛研究的途径是磷酸肌苷3激酶(PI3K)/磷酸酶和紧张素同源物(PTEN)/蛋白激酶B (AKT)和聚ADP核糖聚合酶(PARP)和DNA修复途径。本综述将重点介绍最近的临床试验，这些试验对转移性疾病患者的管理产生了重大影响，重点是晚期前列腺癌中常见基因组畸变驱动的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Changing Therapeutic Landscape in Metastatic Prostate Cancer

O ver the past several years a number of novel and diverse agents have provided a significant clinical benefit for patients with metastatic castration-resistant prostate cancer including abiraterone, enzalutamide, sipuleucel-T, cabazitaxel, and radium-223. The early use of docetaxel or abiraterone at initiation of standard androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer has also led to substantial improvements in overall survival. The identification of a truncating mutation in the androgen receptor (ARV7), a biomarker of resistance, may help clarify a more optimal sequencing of hormonal and chemotherapy-based therapies for patients with metastatic disease. The genomic landscape of both primary and metastatic prostate cancer has been an important focal point of translational research. The most widely studied pathways that affect tumorigenesis are the phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homolog (PTEN)/protein kinase B (AKT) and poly ADP ribose polymerase (PARP) and DNA repair pathways. This review will highlight recent clinical trials which have had a major impact on the management of patients with metastatic disease with an emphasis on treatments driven by common genomic aberrations present in advanced prostate cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oral History Review Multiple-

CiteScore

1.20

自引率

27.30%

发文量

期刊介绍： The Oral History Review, published by the Oral History Association, is the U.S. journal of record for the theory and practice of oral history and related fields. The journal’s primary mission is to explore the nature and significance of oral history and advance understanding of the field among scholars, educators, practitioners, and the general public. The Review publishes narrative and analytical articles and reviews, in print and multimedia formats, that present and use oral history in unique and significant ways and that contribute to the understanding of the nature of oral history and memory. It seeks previously unpublished works that demonstrate high-quality research and that offer new insight into oral history practice, methodology, theory, and pedagogy. Work published in the journal arises from many fields and disciplines, reflecting the interdisciplinary nature of oral history. While based in the U.S., the Review reflects the international scope of the field and encourages work from international authors and about international topics.